Twitter LinkedIn Français English WEBCASTS CONFERENCE CALL AND WEBCAST ON TUESDAY, NOVEMBER 16, 2021 AT 8:30AM EST / 2:30PM CET ERYTECH management will hold a conference call and webcast on Tuesday, November 16, 2021 at 8:30am EST / 2:30 pm CET to discuss the recent business and financial updates. Gil Beyen, CEO, Eric Soyer, CFO/COO, and Iman El-Hariry, CMO, will deliver a brief presentation, followed by a Q&A session. The audio call is accessible via the below registering link: http://www.directeventreg.com/registration/event/6425429 (Conference ID : 6425429) Once registered, participants will receive a unique access code and the call number details to join the teleconference. The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/uyoshe5q. An archived replay of the call will be available for 7 days by dialing + 1 855 859 2056, Conference ID: 6425429#. An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at investors.erytech.com. >> link to slideshow TRYBECA-1 TOP-LINE RESULTS AND ANALYSIS CONFERENCE CALL DETAILS ERYTECH management will hold a conference call and webcast on October 25, at 8:30am EDT / 2:30 pm CEST highlights the top-line results and plans for future approval and launch in 2022. Gil Beyen, CEO, Eric Soyer, CFO/COO, and Iman El-Hariry, CMO, will deliver a brief presentation, followed by a Q&A session. The audio call is accessible via the below registering link: http://www.directeventreg.com/registration/event/2361482 (Conference ID : 2361482). Once registered, participants will receive a unique access code and the call number details to join the teleconference. The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/4cdxqddy An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at investors.erytech.com An archived replay of the audio call will be available for 7 days by dialing + 1 855 859 2056, Conference ID: 2361482#. >> link to slideshow ERYTECH TO HOST ON SEPTEMBER 21, 2021 SECOND QUARTER 2021 CONFERENCE CALL AND BUSINESS UPDATE The audio call is accessible via the below registering link: http://www.directeventreg.com/registration/event/6866536 Conference ID : 6866536 Once registered, participants will receive a unique access code and the call number details to join the teleconference. The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/z2wjhmw4. An archived replay of the call will be available for 7 days by dialing + 1 855 859 2056, Conference ID: 6866536#. An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at investors.erytech.com >> link to slideshow WEBINAR ON ERYASPASE IN PANCREATIC CANCER Presentation on the lead product candidate eryaspase, L-asparaginase encapsulated in donor-derived red blood cells, featured by KOLs and also the Principal Investigators of the TRYbeCA-1 and rESPECT studies, respectively; Dr. Manuel Hidalgo Medina, M.D., Ph.D., Weill Cornell Medicine/NewYork-Presbyterian Hospital, and Dr. Marcus Noel, M.D., Georgetown University. >> Access the replay of the conference ERYTECH TO PARTICIPATE IN UPCOMING VIRTUAL INVESTOR CONFERENCES IN JUNE JEFFERIES VIRTUAL HEALTHCARE CONFERENCE – JUNE 1- 4, 2021 Gil Beyen, Chief Executive Officer, will be participating in a fireside chat followed by a virtual Q&A session on Friday June 4th at 10am (ET). WEBCAST LINK A replay of the session will be on the Jefferies conference website, as well as on ERYTECH’s website, under the “Investors” section at investors.erytech.com, for 30-days following the conference. For more information please visit the Conferences & Events section of the Jefferies website. JMP SECURITIES LIFE SCIENCES CONFERENCE – JUNE 16 & 17, 2021 Gil Beyen, Chief Executive Officer, will present a company overview followed by a virtual Q&A session on Wednesday June 16th at 2pm (ET). WEBCAST LINK A link to the live audio webcast as well as the replay of the webcast will be available on ERYTECH’s website, under the “Investors” section at investors.erytech.com. For more information about the JMP Securities Life Sciences Conference, please refer to the JMP conference website SPRING EUROPEAN MIDCAP EVENT – JUNE 24 & 25, 2021 Gil Beyen, Chief Executive Officer and Eric Soyer Chief Financial Offier will participate in one-on-one meetings on Thursday June 24th. For more information about the Spring European Midcap Event, please refer to the CF&B conference website If you are interested in arranging a one-on-one meeting, please contact your conference representative. ERYTECH ANNOUNCES THE DETAILS OF ITS 2021 Q1 CONFERENCE CALL Publication of Q1 2021 results on 4 May 2021 after market close. ERYTECH management will hold a conference call and webcast on Wednesday May 5, 2020 at 02:30pm CEST / 08:30am EST on the business and financial highlights for the quarter ended March 31, 2021. Gil Beyen, CEO, Eric Soyer, CFO/COO, and Iman El-Hariry, CMO, will deliver a brief presentation, followed by a Q&A session. The call is accessible via the below teleconferencing numbers, followed by the Conference ID#: 3887923# USA/Canada: +1 (833) 818-6807 France: +33 1 70 80 71 53 United-Kingdom: +44 2031070289 International Dial-In Number: +1 (409) 350-3501 The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/yuzu4z3u An archived replay of the call will be available for 7 days by dialing + 1 855 859 2056, Conference ID: 3887923#. An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at investors.erytech.com >> link to slideshow ERYTECH TO HOST FOURTH QUARTER AND FULL YEAR 2020 CONFERENCE CALL AND BUSINESS UPDATE ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its fourth quarter and full year 2020 conference call and webcast on Tuesday, March 9, 2021, at 2:30 PM CET/8:30 AM ET to discuss operational highlights. The call is accessible via the below teleconferencing numbers, followed by the Conference ID#: 8861234# USA/Canada: +1 (833) 818-6807 France: +33 1 70 80 71 53 United-Kingdom: +44 2031070289 International Dial-In Number: +1 (409) 350-3501 The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/tic4qkwg An archived replay of the call will be available for 7 days by dialing + 1 855 859 2056, Conference ID: 8861234#. An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at investors.erytech.com >> link to slideshow ERYTECH TO PRESENT AT THE 2021 BIO CEO & INVESTOR CONFERENCE ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present a corporate overview at the 2021 BIO CEO & Investor Conference and participate in select one-on-one investor meetings. The conference will be held virtually this year with all participants joining remotely from February 16 to 18, 2021. Beginning February 16, a pre-recorded presentation by company management will be available for on-demand viewing by registered attendees anytime through March 14th by accessing the BIO CEO Conference portal. For more information about the BIO CEO & Investor Conference, please refer to the conference website at https://www.bio.org/events/bio-ceo-investor-digital-conference A webcast of the event will be accessible via ERYTECH’s website at https://erytech.com/investors/webcast/ If you are interested in arranging a one-on-one meeting request a meeting on the One-on-One Partnering System hosted by BIO or contact Corey Davis at LifeSciAdvisors. ERYTECH TO PRESENT AT THE H.C. WAINWRIGHT VIRTUAL BIOCONNECT 2021 CONFERENCE ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced today that CEO, Gil Beyen, will present at the H.C. Wainwright Virtual BioConnect 2021 in a pre-recorded corporate overview presentation. Beginning January 11th, a pre-recorded presentation by company management will be available for on-demand viewing by registered attendees anytime through January 14th by accessing the HC Wainwright Virtual Conference portal. Those interested in registering for the conference can do so here: https://hcwevents.com/bioconnect. ERYTECH TO PRESENT AT THE LIFESCI PARTNERS 10TH ANNUAL HEALTHCARE CORPORATE ACCESS EVENT ON WEDNESDAY, JANUARY 6TH AT 9AM EST /2PM GMT /3PM CET. ERYTECH Pharma’s CEO, Gil Beyen, will present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event on Wednesday, January 6th at 9am EST /2pm GMT /3pm CET. The format will be a virtual presentation with the opportunity for Q&A at the conclusion. The event will be held virtually, with all corporate and institutional participants joining remotely. Investors interested can pre-register for the January 6th 9am Eastern Time corporate presentation with the following registration link: http://lifesci.events/LifeSci2021. Access to the presentation’s replay : https://wsw.com/webcast/lifesci/eryp/2097888 ERYTECH WILL HOLD A WEBCAST ON MONDAY, DECEMBER 7, AT 4:00 PM CET / 10:00AM ET. Dr. Birgitte Klug Albertsen, Associate Professor at Aarhus University Hospital, Denmark, and Principal Investigator of the trial, Dr. Iman El-Hariry, Chief Medical Officier of ERYTECH Pharma, and Gil Beyen, Chief Executive Officer of ERYTECH Pharma, will comment on the data and be available for Q&A. The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/yp9nynh6. Conference ID#: 2272914# >> link to slideshow ERYTECH TO PARTICIPATE IN FIRESIDE CHAT AT JEFFERIES VIRTUAL HEALTHCARE CONFERENCE ERYTECH Pharma announced that its CEO, Gil Beyen, will be participating in a fireside chat at the Jefferies Virtual Healthcare Conference at 12:00pm EST / 05:00pm GMT / 6:00pm CET on November 18, 2020 The webcast can be followed via the link (this link will be available for 90 days): https://wsw.com/webcast/jeff141/eryp/1869600 ERYTECH TO HOST THIRD QUARTER 2020 CONFERENCE CALL AND BUSINESS UPDATE ON NOVEMBER 6, 2020 ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a Third Quarter 2020 conference call and webcast on Friday, November 6, 2020, at 2:30 PM CET/8:30 AM EST to discuss operational highlights. The call is accessible via the below teleconferencing numbers, followed by the Conference ID#: 2943988# USA/Canada: +1 (833) 818-6807 France: +33 1 70 80 71 53 United-Kingdom: +44 2031070289 International Dial-In Number: +1 (409) 350-3501 The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/cm8pkxrh An archived replay of the call will be available for 7 days by dialing + 1 855 859 2056, Conference ID: 2943988#. An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at investors.erytech.com >> Link to slideshow ERYTECH TO HOST A KOL EVENT AS THE TRYBECA-1 PHASE 3 TRIAL IN SECOND-LINE PANCREATIC CANCER NEARS COMPLETE ENROLLMENT ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announces the hosting of a Key Opinion Leader (KOL) Event to discuss the medical need in pancreatic cancer and the potential role of eryaspase in this setting. On September 29, 2020 at 10:00 am ET, ERYTECH will host a call that will include a presentation by KOL Dr. Manuel Hidalgo, MD, Ph.D. (Weill Cornell Medicine/New York Presbyterian Hospital), who will discuss the current treatment landscape and unmet medical need in treating patients with pancreatic cancer, and an update by Erytech’s management on eryaspase and the TRYbeCA-1 trial. Dr. Hidalgo and management will be available to answer questions at the conclusion of the call. Registration for the event is available at the following link: https://lifescipartners.zoom.us/webinar/register/2815964896473/WN_9NL0s4RxTBavKypVlPRZ-A An archive of the webcast can viewed via the following link : https://lifescipartners.zoom.us/rec/play/c9w-ng4P4zjwGXzvoy5ZcProcejxaYKd2pCobz1yA600NlaDUcOwDvkF2OqF21DOOQfRiYnUcbJXEEn8.jA0N2S95gL-AQpzH?autoplay=true&startTime=1601388021000 ERYTECH TO HOST ON SEPTEMBER 22, 2020 SECOND QUARTER 2020 CONFERENCE CALL AND BUSINESS UPDATE ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter 2020 conference call and webcast on Tuesday, September 22, 2020, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights. The call is accessible via the below teleconferencing numbers, followed by the Conference ID#: 8585556# USA/Canada: +1 (833) 818-6807 France: +33 1 70 80 71 53 United-Kingdom: +44 2031070289 International Dial-In Number: +1 (409) 350-3501 The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/ypvwj59i An archived replay of the call will be available for 7 days by dialing + 1 855 859 2056, Conference ID: 8585556#. An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at http://investors.erytech.com >> Link to slideshow ERYTECH TO HOST ON MAY 7, 2020 FIRST QUARTER CONFERENCE CALL AND BUSINESS UPDATE ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its 2020 first quarter conference call and webcast on Wednesday, May 7, 2020, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights. The call is accessible via the below teleconferencing numbers, followed by the Conference ID#: 9688486# USA/Canada: +1 (833) 818-6807 France: +33 1 70 80 71 53 United-Kingdom: +44 2031070289 International Dial-In Number: +1 (409) 350-3501 The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/ub95wf2d An archived replay of the call will be available for 7 days by dialing + 1 855 859 2056, Conference ID: 9688486#. An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at http://investors.erytech.com >> Link to slideshow ERYTECH TO HOST FOURTH QUARTER AND FULL YEAR 2019 CONFERENCE CALL AND BUSINESS UPDATE ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its fourth quarter and full year 2019 conference call and webcast on Tuesday, March 17, 2020, at 1:30 PM CET/8:30 AM EST to discuss operational highlights. The call is accessible via the below teleconferencing numbers, followed by the Conference ID#: 1671839# USA/Canada: +1 (833) 818-6807 France: +33 1 70 80 71 53 United-Kingdom: +44 2031070289 International Dial-In Number: +1 (409) 350-3501 The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/h2zjygca An archived replay of the call will be available for 7 days by dialing + 1 855 859 2056, Conference ID: 1671839#. An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at http://investors.erytech.com. >> Link to slideshow Investors Corporate Governance Stock Market Data SEC Filings AMF Regulated Information Shareholders Meeting Financial Calendar Analyst Coverage Webcasts Corporate Presentation Erytech PharmaSA 60 Avenue Rockefeller 69008 Lyon France Erytech Pharma Inc. 1 Main Street, Suite 300 Cambridge, MA 02142 USA About Us Technology Platform Pipeline Investors Newsroom Contact Opens in a new tab Opens in a new tab Terms & Conditions Copyright © 2021. Erytech Pharma. All rights reserved. By visiting this website, you are giving your consent for cookies to be used for us to improve your navigation experience.OKLEARN MORE Français English